Register Financial Advisors LLC Has $1.80 Million Stock Position in Johnson & Johnson $JNJ

Key Points

• Register Financial Advisors LLC reduced its Johnson & Johnson stake by 23.4%, resulting in ownership of 11,792 shares worth $1.80 million.
• Johnson & Johnson reported a Q2 earnings per share (EPS) of $2.77, surpassing the consensus estimate of $2.68, with revenues increasing by 5.8% year-over-year.
• The company recently announced a quarterly dividend of $1.30, translating to an annualized dividend of $5.20 and a yield of 2.9%.

Register Financial Advisors LLC reduced its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 23.4% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 11,792 shares of the company's stock after selling 3,596 shares during the period. Register Financial Advisors LLC's holdings in Johnson & Johnson were worth $1,801,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Highline Wealth Partners LLC boosted its position in shares of Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after purchasing an additional 86 shares during the last quarter. Stone House Investment Management LLC bought a new position in shares of Johnson & Johnson in the 1st quarter worth $47,000. 1248 Management LLC bought a new position in shares of Johnson & Johnson in the 1st quarter worth $48,000. von Borstel & Associates Inc. bought a new position in shares of Johnson & Johnson in the 1st quarter worth $49,000. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of Johnson & Johnson in the 1st quarter worth $52,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

JNJ opened at $179.69 on Friday. The business's 50-day moving average price is $174.41 and its two-hundred day moving average price is $162.06. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $181.16. The company has a market capitalization of $432.75 billion, a price-to-earnings ratio of 19.22, a P/E/G ratio of 2.26 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter last year, the business posted $2.82 EPS. The company's revenue for the quarter was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. Johnson & Johnson's payout ratio is currently 55.61%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. The Goldman Sachs Group lifted their target price on Johnson & Johnson from $185.00 to $186.00 and gave the stock a "buy" rating in a report on Friday, September 19th. Morgan Stanley lifted their target price on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Barclays lifted their target price on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Bank of America lifted their target price on Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a report on Thursday, July 17th. Finally, Guggenheim upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $167.00 to $206.00 in a report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $181.40.

Insider Activity

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.